Jafron Biomedical Co.,Ltd. (SHE:300529)
China · Delayed Price · Currency is CNY 15.63
-0.22 (-1.39%)
Jun 24, 2026, 3:04 PM CST
Jafron Biomedical Stock Forecast
Stock Price Forecast
According to 2 analysts polled by S&P Global, Jafron Biomedical stock has a consensus rating of "Strong Buy" and an average price target of ¥24.12. The average 1-year stock price forecast is 54.32% higher than the current stock price, while the lowest is ¥24.00 (+53.55%) and the highest is ¥24.23 (+55.02%).
Price Target: ¥24.12 (+54.32%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Jafron Biomedical stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Jan '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 1 | 1 | 1 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 1 | 1 | 1 | 2 |
Financial Forecast
Revenue This Year
2.17B
from 2.01B
Increased by 8.06%
Revenue Next Year
2.34B
from 2.17B
Increased by 7.57%
EPS This Year
1.68
EPS Next Year
n/a
from 1.68
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CNY.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 2.2B | ||
| Avg | 2.2B | ||
| Low | 2.1B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 10.8% | ||
| Avg | 8.1% | ||
| Low | 5.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 1.68 | ||
| Avg | 1.68 | ||
| Low | 1.68 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 64.7% | ||
| Avg | 64.7% | ||
| Low | 64.7% |